Related Experiment Video

Updated: May 14, 2026

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Angiogenesis and anti-angiogenic therapy in prostate cancer

Deborah Mukherji1, Sally Temraz, David Wehbe

  • 1Department of Hematology/Oncology, American University of Beirut Medical Center, PO Box 11-0236, Riad El Solh, Beirut 1107 2020, Lebanon. Dm25@aub.edu.lb

Critical Reviews in Oncology/Hematology
|February 5, 2013
PubMed

Insights

Angiogenesis inhibition shows promise for prostate cancer treatment, despite prior failures. Novel agents and combinations may improve outcomes for advanced prostate cancer patients.

Area of Science:

  • Oncology
  • Urology
  • Cancer Research

Background:

  • Angiogenic pathway inhibition is effective for solid tumors, but its role in prostate cancer management is unclear.
  • Five new treatments for metastatic prostate cancer have emerged recently, rapidly changing treatment paradigms.
  • Established antiangiogenic therapies like bevacizumab and sunitinib have not improved survival in prostate cancer trials.

Purpose of the Study:

  • To define the role of angiogenesis inhibition in advanced prostate cancer management.
  • To evaluate novel antiangiogenic agents and treatment combinations for prostate cancer.
  • To validate the biological hypothesis for antiangiogenic therapy benefits in prostate cancer.

Main Methods:

  • Review of recent clinical research and randomized phase III studies.
  • Analysis of established and novel antiangiogenic therapies.
  • Exploration of treatment combinations involving agents like cabozantinib.

Main Results:

  • Several new treatments, including immunotherapy, chemotherapy, and hormone therapies, have improved survival.
  • Established antiangiogenic drugs (bevacizumab, sunitinib) failed to show survival benefits in prostate cancer.
  • Novel agents (cabozantinib) and treatment combinations show promising early results.

Conclusions:

  • While established antiangiogenic therapies have not succeeded, novel approaches warrant further investigation.
  • Further well-designed studies are needed to confirm the benefit of antiangiogenic therapy in prostate cancer.
  • Optimizing antiangiogenic strategies may improve outcomes for patients with advanced prostate cancer.
Keywords:
AngiogenesisBevacizumabCabozantinibCastration resistant prostate cancerSunitinibVascular endothelial growth factor

More Related Videos

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Related Concept Videos

Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...